BMS202 (PD-1/PD-L1 inhibitor 2) - Moligand™, 10mM in DMSO , Agonist of CB 1 receptor;Agonist of CB 2 receptor, CAS No.1675203-84-5, Agonist of CB 1 receptor;Agonist of CB 2 receptor

CAS: 1675203-84-5 Cat. No.: B408242 Molecular Weight: 419.5

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

N-[2-[[[2-methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]-acetamide

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

BMS202 (PD-1/PD-L1 inhibitor 2) BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
In vitro

In vivo

Cell Data

cell lines：LNCaP, 22Rv1, DU145, and PC3

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonyms

N-[2-[[[2-methoxy-6-[(2-methyl[1, 1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]-acetamide

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

AGONIST

Mechanism of action

Agonist of CB 1 receptor;Agonist of CB 2 receptor

Names and Identifiers

• Isomeric SMILES: CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC
• Alternate CAS: 1675203-84-5
• MeSH Entry Terms: BMS202;N-(2-((2-Methoxy-6-(2-methyl-biphenyl-3-ylmethoxy)-pyridin-3-ylmethyl)-amino)-ethyl)-acetamide;PCC0208025
• Molecular Weight: 419.5
• Reaxy-Rn: 27956188
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=27956188&ln=

Associated Targets(Human)

CNR1 Tclin Cannabinoid receptor 1 (1 Activities)

Discover Target: CNR1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CNR2 Tchem Cannabinoid receptor 2 (1 Activities)

Discover Target: CNR2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CD274 Tclin Programmed cell death 1 ligand 1 (0 Activities)

Discover Target: CD274

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

References

1. Yiqiang OuYang, Jian Gao, Lei Zhao, Junfeng Lu, Haiqing Zhong, Hua Tang, Shuanglong Jin, Lu Yue, Yuezhen Li, Wenjie Guo, Qiang Xu, Yisheng Lai.  (2021)  Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.  JOURNAL OF MEDICINAL CHEMISTRY,      [PMID:34037385] [10.1021/acs.jmedchem.1c00370]

2. Ruoxia Wu, Jiaqing Xiong, Ting Zhou, Zhen Zhang, Zhen Huang, Sha Tian, Yongli Wang.  (2023)  Quercetin/Anti-PD-1 Antibody Combination Therapy Regulates the Gut Microbiota, Impacts Macrophage Immunity and Reshapes the Hepatocellular Carcinoma Tumor Microenvironment.  Frontiers in Bioscience-Landmark,  28  (12): (327).  [PMID:38179731] [10.31083/j.fbl2812327]

3. Qiuyang Huang, Xiaoling Zang, Zhiwei Zhang, Hang Yu, Baoyan Ding, Zhuangzhuang Li, Simin Cheng, Xin Zhang, Mustafa R.K. Ali, Xue Qiu, Zhihua Lv.  (2023)  Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,      [PMID:36646351] [10.1016/j.ijbiomac.2023.123266]

4. Sha Liu, Lina Wang, Yupeng Wang, Lina Geng.  (2025)  ROS-responsive multifunctional DCS-based micelle-hydrogel for simultaneously inhibiting post-melanoma-resection recurrence and promoting wound healing.  Nanoscale,      [PMID:41568423] [10.1039/D5NR03938J]